What is the recommended insulin dosing for a patient with poorly controlled diabetes, indicated by a hemoglobin A1c (HbA1c) level of 12, and how do I determine the initial dose and type of insulin, such as glargine (Lantus) (insulin glargine) or detemir (Levemir) (insulin detemir)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Insulin Initiation for Poorly Controlled Diabetes with HbA1c of 12%

For a patient with diabetes and HbA1c of 12%, basal insulin should be initiated at 10 units or 0.1-0.2 units/kg/day, with consideration for adding mealtime insulin due to the severely elevated HbA1c level. 1

Initial Insulin Selection and Dosing

  • For patients with HbA1c ≥10-12%, especially with symptoms or catabolic features, basal insulin plus mealtime insulin is the preferred initial regimen 1
  • Start basal insulin (glargine, detemir, NPH, or degludec) at 10 units daily or 0.1-0.2 units/kg/day, depending on the degree of hyperglycemia 1
  • When initiating insulin therapy, timely dose titration is important to achieve glycemic targets 1
  • Basal insulin is typically used with metformin and perhaps one additional noninsulin agent 1

Insulin Type Selection

  • Long-acting basal insulins (glargine, detemir) provide more stable glycemic control with less hypoglycemia compared to NPH insulin 2, 3
  • Both insulin glargine and insulin detemir are equally effective in lowering HbA1c with comparable risk of hypoglycemia 3, 4
  • Insulin detemir may require higher doses compared to glargine (0.27 ± 0.16 units/kg/day vs. 0.22 ± 0.15 units/kg/day) 4

Titration Algorithm

  • Equip patients with an algorithm for self-titration of insulin doses based on self-monitoring of blood glucose (SMBG) to improve glycemic control 1
  • Adjust basal insulin dose by 2 units every 3 days until fasting blood glucose reaches target (<130 mg/dL) without hypoglycemia 5, 6
  • For patient-managed titration: increase insulin dose by 2 units every 3 days if blood glucose remains above target and no hypoglycemia occurs 1, 7
  • For physician-managed titration: adjust insulin dose by 0-2,4, or 6-8 units based on mean fasting plasma glucose over previous 3 days 7

Adding Mealtime Insulin

  • When HbA1c is 12%, consider starting with both basal and mealtime insulin due to severe hyperglycemia 1
  • If starting with basal insulin alone and HbA1c remains above target after basal insulin has been optimized, add mealtime insulin to control postprandial glucose excursions 1
  • For mealtime insulin, rapid-acting insulin analogs (lispro, aspart, or glulisine) are preferred due to their faster action 1
  • Start mealtime insulin at 4 units per meal or 10% of the basal dose, and titrate by 1-2 units or 10-15% twice weekly based on postprandial glucose readings 6

Monitoring and Adjustments

  • Monitor fasting blood glucose daily to guide basal insulin titration 1, 6
  • Adjust both basal and prandial insulins based on SMBG levels 1
  • If hypoglycemia occurs, determine the cause and reduce the corresponding insulin dose by 10-20% 6
  • Comprehensive education regarding SMBG, diet, exercise, and hypoglycemia management is critical for patients using insulin 1

Special Considerations

  • For patients with HbA1c ≥9%, consider starting at a higher insulin dose or with combination injectable therapy 1, 5
  • When blood glucose levels are ≥300-350 mg/dL and/or HbA1c is 10-12%, especially with symptoms, basal insulin plus mealtime insulin is the preferred initial regimen 1
  • Sulfonylureas, DPP-4 inhibitors, and GLP-1 receptor agonists are usually withdrawn when more complex insulin regimens are used 1
  • Thiazolidinediones or SGLT2 inhibitors may be continued to improve glucose control and reduce total daily insulin dose 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Basal insulin treatment in type 2 diabetes.

Diabetes technology & therapeutics, 2011

Research

COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017

Guideline

Treatment Adjustment for Diabetic Patients with Elevated HbA1c

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Insulin Regimen Adjustment for Poorly Controlled Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.